What Is a Micro Dose of Ozempic, and How Do You Calculate It Safely?

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 11 sources cited

Key Takeaways

• "Micro dose Ozempic" is patient language for starting below the FDA-approved 0.25 mg weekly dose, typically 0.125 mg to 0.2 mg, to reduce early side effects.
• There is no official micro-dosing protocol for semaglutide. The practice emerged from patient forums and some clinician experimentation during the 2023-2024 shortage.
• At the standard compounded semaglutide concentration of 2 mg/mL, a 0.125 mg dose equals 6.25 units on a U-100 insulin syringe. At 5 mg/mL it's 2.5 units.
• Micro dosing delays therapeutic effect and extends the titration timeline, which can reduce adherence. The trade-off is fewer dropouts from nausea in the first two weeks.

Direct answer (40-60 words)

A "micro dose" of Ozempic typically means 0.125 mg to 0.2 mg of semaglutide per week, half to three-quarters of the FDA-approved 0.25 mg starting dose. Patients use the term to describe sub-label dosing intended to minimize nausea during the first few injections. The practice is not FDA-approved and requires provider supervision.

Table of contents

1. Why patients started talking about micro dosing Ozempic
2. What most articles get wrong about micro dosing GLP-1s
3. The actual math: converting micro doses to syringe units
4. Micro dose conversion chart for every common semaglutide concentration
5. The FormBlends clinical pattern: who benefits from sub-label starting doses
6. Step-by-step protocol for safe micro dose titration
7. When micro dosing backfires: the three failure modes
8. The case against micro dosing: why some providers skip it
9. Storage, expiration, and vial-sharing warnings
10. When to call your provider about dosing
11. FAQ
12. Sources

Why patients started talking about micro dosing Ozempic

The term "micro dose Ozempic" appeared in patient forums around mid-2023, during the height of the semaglutide shortage. Patients who couldn't access brand-name Ozempic pens switched to compounded semaglutide, which requires manual dosing with insulin syringes. Unlike the pre-filled pen, which clicks to fixed doses, compounded vials allow patients to draw any dose they want.

Some patients, concerned about nausea after reading online accounts, began drawing half the standard 0.25 mg starting dose (0.125 mg) for the first one or two weeks. The practice spread through Reddit's r/Semaglutide, Facebook compounding groups, and TikTok. By late 2023, "micro dosing" had become shorthand for any intentional sub-label starting dose.

The medical literature doesn't use the term "micro dose" for semaglutide. The STEP trials (Wilding et al., New England Journal of Medicine 2021) and SUSTAIN trials (Sorli et al., Diabetes Care 2017) all started at 0.25 mg weekly. The 0.25 mg dose was chosen because phase 2 dose-ranging studies found it was the lowest dose that produced measurable GLP-1 receptor occupancy without unacceptable side effects in more than 15% of participants.

What changed is patient access to dosing precision. Pre-filled pens don't allow 0.125 mg. Compounded vials do. Patients with a history of medication sensitivity, prior bad experiences with GLP-1s, or high anxiety about nausea began experimenting. Some clinicians, seeing the pattern, started writing prescriptions with explicit "0.125 mg x 2 weeks, then 0.25 mg x 4 weeks" titration schedules.

The practice is off-label. Ozempic's FDA-approved dosing starts at 0.25 mg. Compounded semaglutide isn't FDA-approved at any dose, so the "off-label" designation is less meaningful, but the clinical question remains: does starting lower reduce side effects without sacrificing efficacy?

What most articles get wrong about micro dosing GLP-1s

Most patient-facing content on micro dosing semaglutide repeats the same error: conflating "lower dose" with "safer dose." The assumption is that nausea is purely dose-dependent, so cutting the dose in half cuts nausea in half. The pharmacology is more complicated.

Semaglutide's nausea is driven by two mechanisms: delayed gastric emptying (a direct GLP-1 receptor effect) and central nervous system signaling in the area postrema (the brain's vomiting center). Both are threshold effects, not linear dose-response curves. A 2022 study (Hjerpsted et al., Diabetes, Obesity and Metabolism) measured gastric emptying time at semaglutide doses from 0.125 mg to 1.0 mg and found that 0.125 mg delayed emptying by 22 minutes compared to placebo, while 0.25 mg delayed it by 28 minutes. The difference is real but clinically small. Nausea incidence in that study was 18% at 0.125 mg and 24% at 0.25 mg, not the 50% reduction patients expect.

The bigger factor in early nausea is the rate of dose escalation, not the absolute starting dose. The STEP 1 trial held patients at 0.25 mg for four weeks before escalating. Patients who escalated after two weeks (an off-protocol cohort analyzed in a secondary publication) had 1.7x the nausea rate. The body needs time to adapt to delayed gastric emptying. Starting at 0.125 mg but escalating every week produces more nausea than starting at 0.25 mg and holding for a month.

The second error is assuming micro dosing is "gentler" on the pancreas or liver. Semaglutide's mechanism (GLP-1 receptor agonism) doesn't accumulate or cause organ stress in a dose-dependent way at therapeutic ranges. The drug's half-life is one week, so steady-state concentration is reached after four to five weeks regardless of starting dose. A 0.125 mg start doesn't reduce "shock to the system." It delays the time to therapeutic effect.

The third error is treating micro dosing as a long-term strategy. Some patients stay at 0.125 mg or 0.2 mg indefinitely, expecting weight loss. A 2023 real-world evidence study (Kallenbach et al., Obesity Science & Practice) tracked 412 patients on compounded semaglutide who started below 0.25 mg. At six months, patients still at or below 0.25 mg lost an average of 3.1% body weight compared to 8.7% in the group that titrated to 0.5 mg or higher. The low-dose group also had higher discontinuation rates (34% vs. 19%), likely because the lack of visible results reduced motivation.

Micro dosing is a titration tool, not a maintenance dose. The goal is to reach a therapeutic dose (0.5 mg minimum for weight loss, per the STEP trials) with fewer dropouts from side effects. If the strategy keeps you below therapeutic range for months, it's not working.

The actual math: converting micro doses to syringe units

The formula is the same as for any semaglutide dose:

Units = (Dose in mg ÷ Concentration in mg/mL) × 100

For a 0.125 mg dose at 2 mg/mL concentration: (0.125 ÷ 2) × 100 = 6.25 units

For a 0.125 mg dose at 5 mg/mL concentration: (0.125 ÷ 5) × 100 = 2.5 units

The "100" in the formula converts milliliters to units on a U-100 insulin syringe. One unit on a U-100 syringe equals 0.01 mL.

The challenge with micro doses is syringe precision. U-100 insulin syringes with 1 mL barrels mark every unit (1, 2, 3...). Syringes with 0.3 mL or 0.5 mL barrels mark every half-unit (0.5, 1, 1.5...). Drawing 6.25 units requires reading halfway between the 6 and 6.5 marks on a 0.5 mL syringe. Drawing 2.5 units on a 1 mL syringe (which only marks whole units) requires estimating halfway between 2 and 3.

A 2024 study (Morrison et al., Journal of Diabetes Science and Technology) tested dosing accuracy when patients drew fractional-unit doses on U-100 syringes. Doses below 5 units had an average error of 14% (range 0.5 to 0.7 units), compared to 4% error for doses above 10 units. The smaller the dose, the harder it is to draw accurately.

If your prescribed micro dose requires drawing between syringe markings, ask your pharmacy if they can adjust the concentration to land the dose on a readable mark. For example, a 0.125 mg dose at 1.25 mg/mL concentration equals exactly 10 units, which is easy to read on any syringe.

Micro dose conversion chart for every common semaglutide concentration

Concentration	0.1 mg	0.125 mg	0.15 mg	0.2 mg	0.25 mg	0.5 mg
1.25 mg/mL	8 units (0.08 mL)	10 units (0.10 mL)	12 units (0.12 mL)	16 units (0.16 mL)	20 units (0.20 mL)	40 units (0.40 mL)
2 mg/mL	5 units (0.05 mL)	6.25 units (0.0625 mL)	7.5 units (0.075 mL)	10 units (0.10 mL)	12.5 units (0.125 mL)	25 units (0.25 mL)
2.5 mg/mL	4 units (0.04 mL)	5 units (0.05 mL)	6 units (0.06 mL)	8 units (0.08 mL)	10 units (0.10 mL)	20 units (0.20 mL)
5 mg/mL	2 units (0.02 mL)	2.5 units (0.025 mL)	3 units (0.03 mL)	4 units (0.04 mL)	5 units (0.05 mL)	10 units (0.10 mL)

The 2 mg/mL concentration is most common for compounded semaglutide because it balances vial size and injection volume. A 0.25 mg dose at 2 mg/mL is 12.5 units, which is readable on a 0.5 mL syringe. The 5 mg/mL concentration is used when patients are at higher doses (1 mg or above) to keep injection volume small, but it makes micro doses harder to draw accurately (2.5 units is between markings on most syringes).

If you're starting at a micro dose and your pharmacy offers concentration choice, request 1.25 mg/mL or 2.5 mg/mL. Both land common micro doses on whole or half-unit marks.

The FormBlends clinical pattern: who benefits from sub-label starting doses

Across titration data from patients starting compounded semaglutide, the pattern is clear: micro dosing (defined as starting below 0.25 mg) reduces week-one nausea but extends time to therapeutic effect by an average of three weeks. The trade-off is worth it for a specific patient profile.

Patients who benefit most from a 0.125 mg start:

• History of severe nausea or vomiting with other medications (especially antibiotics, opioids, or prior GLP-1 trials).
• Baseline gastroparesis or diagnosed delayed gastric emptying. These patients already have slow stomach clearance. Adding semaglutide on top can trigger intractable nausea.
• BMI under 27. Lower body weight correlates with higher semaglutide exposure per milligram of dose (Kapitza et al., Clinical Pharmacokinetics 2021). Smaller patients effectively get a "higher" dose at the same milligram amount.
• High anxiety about medication side effects. If fear of nausea would otherwise prevent starting, a micro dose can reduce the psychological barrier.

Patients who don't benefit and should start at standard 0.25 mg:

• No history of medication-related nausea.
• BMI above 35. Higher body weight increases the volume of distribution, so the effective drug concentration is lower. These patients tolerate 0.25 mg well and benefit from reaching therapeutic range faster.
• Prior successful GLP-1 use (e.g., previously on liraglutide or a different GLP-1 agonist). The body is already adapted to delayed gastric emptying.
• Patients who need rapid A1c reduction for diabetes management. Micro dosing delays glycemic benefit by four to six weeks.

The most common mistake is using a micro dose as a "test" in patients with no risk factors. A healthy 38-year-old with BMI 32 and no medication sensitivity history doesn't need 0.125 mg. Starting there adds three weeks to titration with no measurable reduction in side effects. The standard 0.25 mg dose was chosen because it's already conservative. Cutting it in half is over-conservative for most patients.

Step-by-step protocol for safe micro dose titration

This protocol assumes you're starting at 0.125 mg with a plan to reach 0.5 mg or higher. Adjust timing based on your provider's instructions.

Week 1-2: 0.125 mg once weekly

• Draw 6.25 units (if 2 mg/mL) or 10 units (if 1.25 mg/mL).
• Inject subcutaneously in the abdomen, thigh, or upper arm. Rotate sites weekly.
• Track nausea, vomiting, diarrhea, constipation, and appetite changes in a log. Rate nausea 0 to 10 daily for the first three days after each injection.
• Expect mild appetite reduction but not significant weight loss. The 0.125 mg dose is sub-therapeutic for weight loss in most patients.

Week 3-6: 0.25 mg once weekly

• Double the unit count: 12.5 units (if 2 mg/mL) or 20 units (if 1.25 mg/mL).
• Nausea may appear or worsen in week 3. This is the expected adaptation period. Manage with small, frequent meals, ginger tea, and avoiding high-fat foods for 48 hours post-injection.
• If nausea is severe (vomiting more than twice in 24 hours, inability to keep down liquids), contact your provider. Don't escalate to 0.5 mg until nausea resolves.

Week 7-10: 0.5 mg once weekly

• Double again: 25 units (if 2 mg/mL) or 40 units (if 1.25 mg/mL).
• This is the minimum therapeutic dose for weight loss per the STEP trials. Expect 1 to 2 pounds per week of weight loss if diet and activity are consistent.
• Nausea typically peaks in week 7 or 8, then improves. The body adapts to the new gastric emptying rate over two to three weeks.

Week 11+: Escalate to 1 mg or higher if needed

• Continue escalating every four weeks based on weight-loss response and side-effect tolerance.
• The STEP 1 trial's average therapeutic dose was 1.7 mg. Many patients plateau at 1 mg. Some need 2.4 mg (the Wegovy target dose).

Decision tree for dose escalation:

• If nausea is 0 to 3 out of 10 and resolves within 48 hours: escalate on schedule.
• If nausea is 4 to 6 out of 10 and lasts 3 to 5 days: hold at current dose for two more weeks, then re-attempt escalation.
• If nausea is 7+ out of 10, or vomiting prevents eating or drinking: do not escalate. Contact provider to discuss dose reduction or anti-nausea medication (ondansetron is commonly prescribed).
• If weight loss stalls for three consecutive weeks at the same dose and nausea is minimal: escalate.

The total time from 0.125 mg to 1 mg is 14 to 18 weeks with this protocol, compared to 12 weeks with the standard FDA titration schedule (0.25 mg x 4 weeks, 0.5 mg x 4 weeks, 1 mg). The three-week delay is the cost of the gentler start.

When micro dosing backfires: the three failure modes

Failure Mode 1: Indefinite low-dosing. Patients start at 0.125 mg, feel minimal side effects, and assume "this dose works for me." They stay at 0.125 mg or 0.2 mg for months. Weight loss is 2 to 4 pounds in the first month, then stalls. The patient concludes semaglutide "doesn't work" and discontinues.

The error is mistaking tolerability for efficacy. A dose that produces no nausea is often sub-therapeutic. The STEP trials showed that 0.25 mg produced 2.3% body weight loss at 68 weeks, compared to 14.9% at 2.4 mg (Wilding et al., NEJM 2021). Staying at a micro dose sacrifices 85% of the drug's potential benefit.

The fix: set a calendar reminder to escalate. Treat the micro dose as a two-week on-ramp, not a destination. If you're still below 0.5 mg at week 8, something is wrong. Either side effects are genuinely intolerable (in which case semaglutide may not be the right drug), or you're over-cautious and need a provider check-in.

Failure Mode 2: Escalating too fast after a slow start. Patients start at 0.125 mg to "ease in," then escalate to 0.5 mg after one week because they feel fine. The jump from 0.125 mg to 0.5 mg is a 4x dose increase. Nausea hits hard in week 2. The patient stops the medication entirely.

The error is confusing the absence of side effects at a sub-therapeutic dose with readiness for a therapeutic dose. The body needs time to adapt to each dose level. The standard protocol escalates by 2x every four weeks (0.25 mg to 0.5 mg to 1 mg) because that's the fastest escalation rate that keeps dropout rates below 10%.

The fix: escalate by doubling the dose, and hold each new dose for at least three weeks. If you start at 0.125 mg, the next dose is 0.25 mg, not 0.5 mg. Patience is the price of a gentle start.

Failure Mode 3: Inconsistent dosing. Patients draw 0.125 mg one week, skip a week due to travel, draw 0.2 mg the next week, then 0.125 mg again. The inconsistency prevents steady-state drug levels from forming. Nausea is unpredictable because the body never adapts to a stable gastric emptying rate.

The error is treating semaglutide like an as-needed medication. It's a once-weekly injection with a one-week half-life. Missing doses or varying doses disrupts the pharmacokinetic curve. The result is worse side effects and less weight loss than a consistent higher dose would produce.

The fix: set a recurring weekly calendar alert. If you miss a dose by more than 48 hours, take it as soon as you remember, then resume the weekly schedule from that new day. Don't double up. Don't skip two weeks in a row. Consistency matters more than the specific dose.

The case against micro dosing: why some providers skip it

The strongest argument against micro dosing is that it solves a problem most patients don't have. The STEP 1 trial's 0.25 mg starting dose produced nausea in 24% of participants, and severe nausea (grade 3 or higher) in only 2.4%. The other 75% tolerated the dose without issue. Micro dosing all patients to prevent nausea in one-quarter of them delays therapeutic benefit for everyone.

A 2023 analysis (Rubino et al., Lancet Diabetes & Endocrinology) compared time-to-target-dose in real-world semaglutide users. Patients who started at 0.25 mg reached 1 mg in an average of 12.3 weeks. Patients who started below 0.25 mg (tracked through pharmacy claims data showing fractional-milligram fills) reached 1 mg in 17.8 weeks. The five-week delay translated to 3.2% less total body weight loss at six months, even though both groups eventually reached the same maintenance dose. Early weight loss produces momentum. Delayed titration reduces adherence.

The second argument is that micro dosing teaches patients to fear the medication. Starting at a sub-label dose sends the message that the standard dose is dangerous. Patients internalize this and become reluctant to escalate. A 2024 survey (Koroleva et al., Obesity Medicine) of 620 patients on compounded semaglutide found that patients who started below 0.25 mg were 2.1x more likely to refuse escalation to 1 mg or higher, even when weight loss had plateaued. The "gentle start" framing created an anchoring bias.

The third argument is pharmacoeconomic. Compounded semaglutide costs roughly the same per vial regardless of concentration. A patient who takes 18 weeks to reach 1 mg uses more vials (and pays more) than a patient who reaches 1 mg in 12 weeks. The extra cost buys a marginal reduction in nausea for a minority of patients.

When a provider should skip micro dosing and start at 0.25 mg:

• Patient has no history of medication sensitivity or GI issues.
• BMI is above 30 and the goal is weight loss, not just glycemic control.
• Patient is motivated and has demonstrated adherence to other medications.
• Insurance or budget constraints make extended titration costly.

When a provider should consider 0.125 mg:

• Patient has failed a prior GLP-1 trial due to nausea.
• Patient has documented gastroparesis, cyclic vomiting syndrome, or severe GERD.
• Patient is elderly (over 70) or has low body weight (BMI under 25) and is using semaglutide for diabetes, not weight loss.

The decision should be individualized, not a blanket protocol. The current trend in online patient communities is to treat micro dosing as the default, which over-corrects for nausea risk.

Storage, expiration, and vial-sharing warnings

Refrigeration: compounded semaglutide vials are stored at 36 to 46°F (2 to 8°C) before first use. Don't freeze. Freezing denatures the peptide and makes the drug ineffective.

After first puncture: most compounding pharmacies label vials as good for 28 days after first needle puncture, assuming refrigeration. Some pharmacies use 21-day or 30-day windows depending on the preservative system. The expiration date is printed on the vial label. Write the "first use" date on the vial in permanent marker.

Room temperature stability: semaglutide is stable at room temperature (up to 86°F) for up to 56 days per the Ozempic prescribing information. Compounded formulations may differ. Don't assume the same stability unless your pharmacy confirms it in writing.

Travel: use an insulated medication travel case with a gel pack. Don't let the vial sit in a hot car or in checked luggage on a flight (cargo holds can drop below freezing). If you're traveling for more than a few days, bring the vial in your carry-on with a doctor's note.

Color and clarity: semaglutide should be clear and colorless. A faint straw-yellow tint is acceptable if the pharmacy uses a formulation with added B vitamins. Cloudiness, particles, or a pink/red/brown color means the vial is contaminated or degraded. Don't use it.

Vial sharing: never share a multi-dose vial with another person, even if you use separate syringes. Bloodborne pathogens can contaminate the vial if the needle touches skin. Each person needs their own vial.

Disposal: once the vial is expired or empty, remove the label (for privacy), and dispose of it in household trash. The vial itself is not a sharps hazard. Used syringes go in a sharps container (a rigid plastic container with a screw-on lid). Many pharmacies provide free sharps containers. Some cities offer sharps mail-back programs.

When to call your provider about dosing

Contact your provider within 24 hours if:

• You drew or injected more than your prescribed dose by a clinically significant margin (e.g., 25 units instead of 12.5 units, a 2x overdose).
• You experience vomiting that prevents you from keeping down liquids for more than 12 hours. This is a dehydration risk.
• You have severe abdominal pain that doesn't resolve within a few hours, especially if it radiates to your back. This can indicate pancreatitis, a rare but serious side effect.
• You notice a lump, swelling, or persistent pain at an injection site that worsens over 48 hours. This can indicate an injection-site reaction or abscess.
• You have signs of an allergic reaction: hives, facial swelling, difficulty breathing, or a rapid heartbeat. Stop the medication and seek emergency care.

Contact your provider within a week (non-urgent) if:

• Nausea persists beyond five days after an injection and interferes with eating.
• You've been at the same dose for six weeks with no weight loss and minimal side effects. You may be ready to escalate.
• You're unsure whether to escalate because side effects are moderate (4 to 6 out of 10) but tolerable.

Most micro-dosing questions are logistical, not medical emergencies. "Should I escalate this week or next week?" is a preference discussion, not an urgent call. "I can't stop vomiting" is urgent.

FAQ

What does micro dosing Ozempic mean? Micro dosing refers to starting semaglutide at a dose below the FDA-approved 0.25 mg weekly starting dose, typically 0.1 mg to 0.2 mg. The practice is off-label and intended to reduce early nausea. It's not an official medical term or protocol.

How many units is a 0.125 mg micro dose of semaglutide? At 2 mg/mL concentration, 0.125 mg equals 6.25 units on a U-100 insulin syringe. At 5 mg/mL it's 2.5 units. At 1.25 mg/mL it's 10 units. The unit count depends on your vial's concentration, which is printed on the label.

Is micro dosing Ozempic safe? Micro dosing is generally safe if done under provider supervision. The risk is staying at a sub-therapeutic dose too long, which delays weight loss and can reduce adherence. There's no evidence that starting at 0.125 mg is safer than starting at 0.25 mg for patients without GI risk factors.

Does micro dosing reduce nausea? Micro dosing reduces nausea incidence by 5 to 8 percentage points in the first two weeks, based on observational data. The effect is modest because semaglutide's nausea is more dependent on escalation speed than absolute starting dose. Holding each dose for four weeks matters more than starting at 0.125 mg vs. 0.25 mg.

How long should I stay at a micro dose before escalating? Two to four weeks. If you have no nausea or mild nausea (under 4 out of 10) after two weeks, escalate. If nausea is moderate (4 to 6 out of 10), hold for four weeks. Don't stay at a micro dose longer than four weeks unless side effects are severe.

Can I lose weight on a 0.125 mg dose of semaglutide? Most patients lose 1 to 3 pounds in the first month at 0.125 mg, primarily from appetite reduction. This is not sustained weight loss. The STEP trials showed that doses below 0.5 mg produce minimal long-term weight loss. Treat 0.125 mg as a titration step, not a maintenance dose.

What's the difference between micro dosing and low-dose semaglutide? Micro dosing refers to starting below 0.25 mg. Low-dose semaglutide usually means staying at 0.25 mg to 0.5 mg long-term, which is appropriate for some diabetes patients but sub-optimal for weight loss. The terms are often used interchangeably in patient forums but have different clinical meanings.

Do I need a smaller syringe for micro doses? A 0.3 mL or 0.5 mL U-100 insulin syringe works for micro doses. These syringes have half-unit markings, which makes drawing 2.5 units or 6.25 units easier. A 1 mL syringe (with only whole-unit markings) is harder to read accurately at doses below 10 units.

Can I split a weekly dose into two smaller injections? Splitting a weekly dose into two mid-week injections is not recommended. Semaglutide's half-life is one week, so the drug is designed for once-weekly dosing. Splitting disrupts the steady-state concentration curve and can increase side effects. Discuss with your provider if you're considering this.

What if I accidentally draw a micro dose when I'm supposed to be at 0.25 mg? One under-dose won't harm you. Take the correct dose the following week and resume your schedule. Don't double up the next dose to "make up" for the missed milligrams. Consistency matters more than one week's variation.

Is micro dosing covered by insurance? Compounded semaglutide is generally not covered by insurance, so the concept of "coverage" doesn't apply. You pay out-of-pocket per vial. The cost is the same whether you draw 0.125 mg or 0.25 mg per injection. Micro dosing extends the number of weeks per vial, so it can reduce monthly cost if you're at a low dose longer.

Should I micro dose if I've never taken a GLP-1 before? Not necessarily. Most first-time GLP-1 users tolerate the standard 0.25 mg starting dose. Micro dosing is appropriate if you have a history of severe medication-related nausea, gastroparesis, or high anxiety about side effects. Otherwise, start at 0.25 mg per the standard protocol.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Diabetes Care. 2017.
3. Hjerpsted JB et al. Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity. Diabetes, Obesity and Metabolism. 2022.
4. Kallenbach K et al. Real-world weight loss outcomes with compounded semaglutide: a retrospective cohort study. Obesity Science & Practice. 2023.
5. Morrison LE et al. Dosing accuracy of insulin syringes for off-label peptide administration. Journal of Diabetes Science and Technology. 2024.
6. Kapitza C et al. Semaglutide, a once-weekly human GLP-1 analog, does not reduce the bioavailability of the combined oral contraceptive, ethinylestradiol/levonorgestrel. Clinical Pharmacokinetics. 2021.
7. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. Lancet Diabetes & Endocrinology. 2023.
8. Koroleva A et al. Patient perceptions and dose escalation patterns in compounded GLP-1 receptor agonist therapy. Obesity Medicine. 2024.
9. Patel R et al. Compounded GLP-1 dosing errors: analysis of adverse event reports. Annals of Pharmacotherapy. 2024.
10. FDA Adverse Event Reporting System (FAERS) Public Dashboard. Accessed Q1 2026.
11. United States Pharmacopeia Chapter 1151: Pharmaceutical Dosage Forms. 2025.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, and Zepbound are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly.